Skip to main content

Table 1 Program characteristics of included articles (N = 25)

From: Early innovations in opioid use disorder treatment and harm reduction during the COVID-19 pandemic: a scoping review

Article study design/type N (%)
Commentary or program description 18 (72%)
Research with quantitative outcomes 4 (16%)
Research with qualitative outcomes 2 (8%)
Case report 1 (4%)
 Country
 United States 13 (52%)
 Puerto Rico 1 (4%)
 South Africa 1 (4%)
 United Kingdom 1 (4%)
 Ireland 1 (4%)
 India 2 (8%)
 Australia 3 (12%)
 Canada 1 (4%)
 Spain 1 (4%)
 Italy 1 (4%)
Care setting
 Substance use treatment 13 (52%)
 Outreach/harm reduction 7 (28%)
 Correctional facility 2 (8%)
 Mobile clinic 2 (8%)
 Primary care/general practitioner 1 (4%)
Type of organization
 Academic institution 7 (28%)
 Government/academic partnership 3 (12%)
 Government 4 (16%)
 Non-for-profit organization 3 (12%)
 Independent clinic 7 (28%)
 Commercial laboratory 1 (4%)
Services described
 OUD Treatment 21 (84%)
 Harm reduction 1 (4%)
 OUD Treatment and Harm reduction 3 (12%)
Types of medications offered
 Sublingual buprenorphine 16 (64%)
 Extended release buprenorphine 3 (12%)
 Methadone 11 (44%)
 Extended-release naltrexone 1 (4%)
 Naloxone 12 (48%)
New vs. modification of program
 New 4 (16%)
 Modification 21 (84%)